INCEPTION

Virago was founded in 2018 with the primary mission of ending breast cancer in our lifetime. The founding partners met and forged their relationships through a series of happy accidents that proved fated to provoke innovation and focus problem solving. A mixture of physicians and entrepreneurs, we examined existing inefficiencies in the clinical approach to breast cancer (i.e., treatment vs. prevention), as well as the relevant and often undervalued sociological aspects of the problem (environmental exposure, access to care, etc..).

In the early phases of our research, we recognized the broad scope of this virus’s reach, and the many diseases in which it is implicated. We also established novel methods of harnessing its therapeutic potential. As of 2024, Virago has successfully secured intellectual property that will serve as the basis for its revolutionary inventions.

GOALS

Virago Vax seeks to explore tumor viruses and their role across diseases and across species. By shifting the conversation from treatment to prevention, we hope to gain insight into a more definitive approach to cancer elimination. This methodology involves reframing the cancer conversation with a new perspective in hopes of achieving our ultimate goal: Powerful vaccines and the end of these diseases within a generation.

to contact us, please email: drsophie@virago-vax.com